SAB Biotherapeutics (SABS) Long-Term Debt Issuances (2020 - 2025)

SAB Biotherapeutics (SABS) has 6 years of Long-Term Debt Issuances data on file, last reported at $3.0 in Q3 2025.

• Quarterly Long-Term Debt Issuances fell 100.0% year-over-year to $3.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $275849.0 (down 46.54% YoY) and the FY2025 annual result came in at $275849.0, down 46.54% from the prior year.
• Long-Term Debt Issuances eased to $3.0 in Q3 2025, from $138551.0 in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $3.7 million in Q4 2022 to a low of -$534863.0 in Q4 2024.
• A 5-year average of $598962.0 and a median of $254913.0 in 2022 frame the typical range for Long-Term Debt Issuances.
• Annual changes were most pronounced in 2021 — Long-Term Debt Issuances surged 1693.75% — and 2024, when it slumped 308.94%.
• Tracing SABS's Long-Term Debt Issuances over 5 years: stood at $2.7 million in 2021, then surged by 39.35% to $3.7 million in 2022, then sank by 93.17% to $255989.0 in 2023, then tumbled by 308.94% to -$534863.0 in 2024, then soared by 100.0% to $3.0 in 2025.
• The last three Long-Term Debt Issuances figures came in at $3.0 (Q3 2025), $138551.0 (Q2 2025), and $137295.0 (Q1 2025), per Business Quant data.